×
About 64,662 results

ALLMedicine™ Inflammatory Bowel Disease Center

Research & Reviews  30,729 results

Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: bo...
https://doi.org/10.1016/j.radonc.2021.02.026
Radiotherapy and Oncology : Journal of the European Socie... Bresolin A, Faiella A et. al.

Feb 27th, 2021 - To assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. Complete data of 415 patients enrolled in a multi institute...

Heme supplementation ameliorates lupus nephritis through rectifying the disorder of spl...
https://doi.org/10.1016/j.intimp.2021.107482
International Immunopharmacology; Wu B, Wu Y et. al.

Feb 27th, 2021 - Heme is an important iron-containing porphyrin molecule expressed ubiquitously in organisms. Recently, this endogenous molecule has been widely reported to be involved in the pathogenesis of numerous diseases such as sepsis, atherosclerosis and in...

Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease Afte...
https://doi.org/10.1007/s10620-021-06895-6 10.1038/ajg.2015.233 10.1053/j.gastro.2013.07.041 10.1007/s11605-016-3275-z 10.1038/ajg.2017.394 10.1097/DCR.0000000000000975 10.1053/j.gastro.2018.04.012 10.1046/j.1524-475x.2000.00547.x 10.1136/gutjnl-2018-316772 10.1111/apt.12313 10.1111/apt.15184 10.1093/ibd/izaa020 10.1093/ibd/izy246 10.1038/nrgastro.2016.158 10.1016/j.cgh.2011.07.016 10.1136/bmjopen-2012-000823 10.1136/bmj.39345.714039.55 10.1053/j.gastro.2015.06.001 10.1371/journal.pmed.1000097 10.1136/bmj.d5928 10.1186/1471-2288-14-45 10.1002/sim.1761 10.1136/bmj.327.7414.557 10.1002/sim.2380 10.1136/bmj.39489.470347.AD 10.1136/bmj.328.7454.1490 10.1177/1536867X1501500203 10.1053/j.gastro.2005.03.003 10.1111/codi.13929 10.1111/j.1365-2036.2004.01904.x 10.1093/ecco-jcc/jjz129 10.1097/SLA.0000000000002017 10.1038/ajg.2016.541 10.1097/DCR.0b013e31829f682c 10.1159/000437362 10.1097/MCG.0b013e3182677003 10.1016/j.crohns.2011.08.014 10.1111/j.1463-1318.2010.02469.x 10.3109/00365521.2012.660540 10.1007/s11605-010-1385-6 10.1097/DCR.0b013e3182a0e702 10.1007/s10620-016-4400-2 10.1097/DCR.0b013e3182759029 10.1001/jamasurg.2017.1538 10.1007/s11605-008-0630-8 10.1111/apt.14459 10.1097/DCR.0000000000001482 10.1002/bjs.9439 10.1007/s11605-010-1341-5 10.1097/01.MIB.0000437497.07181.05 10.1007/s00384-018-3212-6 10.1111/j.1463-1318.2010.02186.x 10.1007/s00384-011-1236-2 10.1093/jcag/gwy013 10.1007/s11605-016-3194-z 10.1038/ajg.2012.464 10.1007/s00384-019-03481-1 10.1111/codi.13937 10.1038/ajg.2017.201 10.1111/j.1365-2036.2009.04204.x 10.1002/ibd.22954 10.1016/j.crohns.2013.01.014 10.1093/ecco-jcc/jjz087 10.1177/1756284820937089 10.4174/jkss.2012.83.3.141 10.1016/j.amjsurg.2012.10.014 10.1097/SLA.0000000000000757 10.1016/S0016-5085(19)36987-2 10.1093/ibd/izy156 10.1016/j.arth.2013.07.011 10.1093/ecco-jcc/jjy148
Digestive Diseases and Sciences; Hanzel J, Almradi A et. al.

Feb 26th, 2021 - Postoperative complication rates in patients with inflammatory bowel disease (IBD) receiving preoperative biologics have been analyzed without considering the surgical context. Emergency surgery may be associated with an increased risk of infectio...

Is the impact of biologic agents in enteropathic spondylitis different from other spond...
https://www.ncbi.nlm.nih.gov/pubmed/33635221
Clinical and Experimental Rheumatology; Farisoğulları B, Yardımcı GK et. al.

Feb 26th, 2021 - To compare enteropathic spondylitis (ES) with psoriatic spondylitis (PS) and ankylosing spondylitis (AS), in patients on biological disease-modifying anti-rheumatic drug (bDMARD) treatment. Patients who were enrolled in the HUR-BIO registry were i...

see more →

Guidelines  137 results

AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review.
https://doi.org/10.1016/j.cgh.2021.02.014
Clinical Gastroenterology and Hepatology : the Official C... Liang PS, Shaukat A et. al.

Feb 13th, 2021 - The purpose of this expert review is to describe the role of medications for the chemoprevention of colorectal neoplasia. Neoplasia is defined as precancerous lesions (e.g., adenoma and sessile serrated lesion) or cancer. The scope of this review ...

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specifi...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.

Feb 6th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665406
Journal of Crohn's & Colitis; Ng SC, Mak JWY et. al.

Oct 21st, 2020 - Endoscopy is an essential component in the management of inflammatory bowel disease [IBD]. There is a risk of SARS-CoV-2 transmission during endoscopic procedures. The International Organization for the study of IBD [IOIBD] has developed 11 positi...

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Pat...
https://doi.org/10.1053/j.gastro.2020.08.060
Gastroenterology Ananthakrishnan AN, Nguyen GC et. al.

Oct 4th, 2020 - AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review.|2020|Ananthakrishnan AN,Nguyen GC,Bernstein CN,|

Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543377
Journal of Crohn's & Colitis; Dotan I, Panaccione R et. al.

Sep 22nd, 2020 - Infusion centres are a central part in the management of patients with inflammatory bowel disease [IBD] and could be a source of transmission of SARS-COV-2. Here we aimed to develop global guidance for best practices of infusion centres for IBD pa...

see more →

Drugs  55 results see all →

Clinicaltrials.gov  31,959 results

Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: bo...
https://doi.org/10.1016/j.radonc.2021.02.026
Radiotherapy and Oncology : Journal of the European Socie... Bresolin A, Faiella A et. al.

Feb 27th, 2021 - To assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. Complete data of 415 patients enrolled in a multi institute...

Heme supplementation ameliorates lupus nephritis through rectifying the disorder of spl...
https://doi.org/10.1016/j.intimp.2021.107482
International Immunopharmacology; Wu B, Wu Y et. al.

Feb 27th, 2021 - Heme is an important iron-containing porphyrin molecule expressed ubiquitously in organisms. Recently, this endogenous molecule has been widely reported to be involved in the pathogenesis of numerous diseases such as sepsis, atherosclerosis and in...

Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease Afte...
https://doi.org/10.1007/s10620-021-06895-6 10.1038/ajg.2015.233 10.1053/j.gastro.2013.07.041 10.1007/s11605-016-3275-z 10.1038/ajg.2017.394 10.1097/DCR.0000000000000975 10.1053/j.gastro.2018.04.012 10.1046/j.1524-475x.2000.00547.x 10.1136/gutjnl-2018-316772 10.1111/apt.12313 10.1111/apt.15184 10.1093/ibd/izaa020 10.1093/ibd/izy246 10.1038/nrgastro.2016.158 10.1016/j.cgh.2011.07.016 10.1136/bmjopen-2012-000823 10.1136/bmj.39345.714039.55 10.1053/j.gastro.2015.06.001 10.1371/journal.pmed.1000097 10.1136/bmj.d5928 10.1186/1471-2288-14-45 10.1002/sim.1761 10.1136/bmj.327.7414.557 10.1002/sim.2380 10.1136/bmj.39489.470347.AD 10.1136/bmj.328.7454.1490 10.1177/1536867X1501500203 10.1053/j.gastro.2005.03.003 10.1111/codi.13929 10.1111/j.1365-2036.2004.01904.x 10.1093/ecco-jcc/jjz129 10.1097/SLA.0000000000002017 10.1038/ajg.2016.541 10.1097/DCR.0b013e31829f682c 10.1159/000437362 10.1097/MCG.0b013e3182677003 10.1016/j.crohns.2011.08.014 10.1111/j.1463-1318.2010.02469.x 10.3109/00365521.2012.660540 10.1007/s11605-010-1385-6 10.1097/DCR.0b013e3182a0e702 10.1007/s10620-016-4400-2 10.1097/DCR.0b013e3182759029 10.1001/jamasurg.2017.1538 10.1007/s11605-008-0630-8 10.1111/apt.14459 10.1097/DCR.0000000000001482 10.1002/bjs.9439 10.1007/s11605-010-1341-5 10.1097/01.MIB.0000437497.07181.05 10.1007/s00384-018-3212-6 10.1111/j.1463-1318.2010.02186.x 10.1007/s00384-011-1236-2 10.1093/jcag/gwy013 10.1007/s11605-016-3194-z 10.1038/ajg.2012.464 10.1007/s00384-019-03481-1 10.1111/codi.13937 10.1038/ajg.2017.201 10.1111/j.1365-2036.2009.04204.x 10.1002/ibd.22954 10.1016/j.crohns.2013.01.014 10.1093/ecco-jcc/jjz087 10.1177/1756284820937089 10.4174/jkss.2012.83.3.141 10.1016/j.amjsurg.2012.10.014 10.1097/SLA.0000000000000757 10.1016/S0016-5085(19)36987-2 10.1093/ibd/izy156 10.1016/j.arth.2013.07.011 10.1093/ecco-jcc/jjy148
Digestive Diseases and Sciences; Hanzel J, Almradi A et. al.

Feb 26th, 2021 - Postoperative complication rates in patients with inflammatory bowel disease (IBD) receiving preoperative biologics have been analyzed without considering the surgical context. Emergency surgery may be associated with an increased risk of infectio...

Is the impact of biologic agents in enteropathic spondylitis different from other spond...
https://www.ncbi.nlm.nih.gov/pubmed/33635221
Clinical and Experimental Rheumatology; Farisoğulları B, Yardımcı GK et. al.

Feb 26th, 2021 - To compare enteropathic spondylitis (ES) with psoriatic spondylitis (PS) and ankylosing spondylitis (AS), in patients on biological disease-modifying anti-rheumatic drug (bDMARD) treatment. Patients who were enrolled in the HUR-BIO registry were i...

see more →

News  1,731 results

Macrophages That Heal Intestinal Inflammation Are Promising Target for IBD Therapy
https://www.medscape.com/viewarticle/946169

Feb 21st, 2021 - NEW YORK (Reuters Health) - A subset of macrophages, PTGER4+ (EP4+), are the major drivers of epithelial regeneration after intestinal inflammation and are potential targets for inflammatory bowel disease (IBD) therapy, researchers say. "Dysfuncti...

Ustekinumab Works Well in Ulcerative Colitis in the General Population
https://www.medscape.com/viewarticle/946043

Feb 18th, 2021 - NEW YORK (Reuters Health) - The monoclonal antibody ustekinumab (Stelara, Janssen) appears to be at least as effective against ulcerative colitis (UC) in real-world practice as it was in the clinical trials that led to its approval, according to n...

Checkpoint Inhibitor Safety in Preexisting Autoimmune Diseases
https://www.medscape.com/viewarticle/945979

Feb 16th, 2021 - Patients with advanced melanoma and preexisting autoimmune diseases (AIDs) who were treated with immune checkpoint inhibitors (ICIs) responded well and did not suffer more grade 3 or higher immune-related adverse events than patients without an AI...

Hirschsprung Disease Tied to Increased Risk of Inflammatory Bowel Disease
https://www.medscape.com/viewarticle/945801

Feb 15th, 2021 - (Reuters Health) - Children with Hirschsprung disease may be at increased risk for developing inflammatory bowel disease, a Canadian study suggests. Researchers examined data on 716 children diagnosed with Hirschsprung since 1991 in Ontario, as we...

Vedolizumab Looks Safer Than Anti-TNF Drugs in Older Adults With IBD
https://www.medscape.com/viewarticle/945729

Feb 11th, 2021 - A large analysis of Medicare data from all 50 states suggests that vedolizumab may be just as effective as anti–tumor necrosis factor (anti-TNF) agents in controlling inflammatory bowel disease (IBD) in patients aged over 65 years, with fewer infe...

see more →

Patient Education  51 results see all →